Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-blind Placebo-controlled Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects

Next Previous
X
Search
Trial Profile

A Randomized Double-blind Placebo-controlled Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enibarcimab (Primary)
  • Indications Septic shock
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 19 Dec 2018 According to an Adrenomed media release, results of the two phase I trials (NCT02991508 and NCT03083171) were presented by Dr. Jens Zimmermann (Chief Medical Officer of Adrenomed AG) at the 2nd scientific symposium (Endothelial Dysfunction-Adrenomedullin as a diagnostic and therapeutic target) which was hosted by Adrenomed AG.
    • 01 Jun 2018 Results assessing safety, tolerability and PK/PD of Adrecizumab in two randomised studies ( NCT02991508 and NCT03083171) published in the British Journal of Clinical Pharmacology
    • 25 Sep 2017 Results published in an Adrenomed Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top